The sales of Yuhan Corp’s new anti-cancer drug 'Leclaza' have jumped significantly. Sales have more than tripled in one year since the drug has been granted reimbursement as a first-line treatment for lung cancer this year. Leclaza’s sales quickly reached the KRW 20 billion mark in quarterly sales, paving the way for the drug to achieve the KRW 100 billion mark in annual sales.

According to the drug research institution IQVIA on Wednesday, Leclaza reported sales of KRW 18.9 billion in Q1, up 269.9% from the KRW 5.1 billion in Q1 last year. Leclaza’s first-quarter sales more than tripled from the previous quarter.